Literature DB >> 7700734

Maternal-fetal interactions affect growth of human immunodeficiency virus type 1 transgenic mice.

R R Franks1, P E Ray, C C Babbott, J L Bryant, A L Notkins, T J Santoro, P E Klotman.   

Abstract

Infants vertically infected with human immunodeficiency virus type 1 (HIV-1) often manifest profoundly deficient growth with failure to thrive. The pathologic mechanisms that produce growth failure associated with pediatric HIV infection are not clear. Transgenic mice homozygous for a gag/pol deletion mutant of the infectious provirus pNL4-3 have been found to manifest a similar growth failure pattern. To explore the influence of HIV-1 on fetal growth and maternal-fetal interactions, we examined intrauterine growth of transgenic and nontransgenic mice and evaluated the consequence of embryo transfer into normal and heterozygous transgenic mothers. Mice homozygous for the HIV transgene had normal intrauterine and birth weights but uniformly displayed severe growth retardation postnatally. Transgene expression was prominent in transgenic fetuses and their placentas and in uteri of transgenic mothers, as determined by Northern analysis. Although embryo transfer did not affect intrauterine growth, the pregnancy rate in transgenic mothers was markedly lower than in nontransgenic controls. In both fetal and neonatal tissues, transgene expression was significantly greater in homozygous animals when compared with heterozygotes, but the difference was magnified postnatally. These results suggest that HIV gene expression affected both mother and neonate. In the mother, expression of the HIV-1 transgene reduced postfertilization pregnancy rate. Once the animal was pregnant, however, the effects of transgene expression on the homozygous fetus were overcome in utero, possibly by the contribution of maternal factors or by inhibition of HIV-1 gene expression by a fetal or maternal factor(s). In the neonate, HIV-1 transgene expression increased dramatically in homozygotes and was associated with profound growth failure.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1995        PMID: 7700734     DOI: 10.1203/00006450-199501000-00012

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  6 in total

1.  Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children.

Authors:  Patricio E Ray; Chien-An A Hu
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

2.  Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression.

Authors:  L A Bruggeman; S Dikman; C Meng; S E Quaggin; T M Coffman; P E Klotman
Journal:  J Clin Invest       Date:  1997-07-01       Impact factor: 14.808

3.  Inhibition of murine embryonic growth by human immunodeficiency virus envelope protein and its prevention by vasoactive intestinal peptide and activity-dependent neurotrophic factor.

Authors:  D A Dibbern; G W Glazner; I Gozes; D E Brenneman; J M Hill
Journal:  J Clin Invest       Date:  1997-06-15       Impact factor: 14.808

4.  Elevated levels of tumor necrosis factor alpha (TNF-alpha) in human immunodeficiency virus type 1-transgenic mice: prevention of death by antibody to TNF-alpha.

Authors:  Swapan K De; Krishnakumar Devadas; Abner Louis Notkins
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

5.  Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline.

Authors:  Byung Oh Kim; Ying Liu; Yiwen Ruan; Zao C Xu; Laurel Schantz; Johnny J He
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

6.  Human chorionic gonadotropin hormone prevents wasting syndrome and death in HIV-1 transgenic mice.

Authors:  S K De; C R Wohlenberg; N J Marinos; D Doodnauth; J L Bryant; A L Notkins
Journal:  J Clin Invest       Date:  1997-04-01       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.